Live from the NIH registry
Studies recruiting near Columbus right now
Top 25 of 1,347 recruiting studies, sorted by proximity — each links to its official registry page
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Phase 2
Interventional 120 participants sought
Nationwide Children's Hospital — Columbus, Ohio (1.9 mi)
· Sponsor: Nationwide Children's Hospital
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Phase 1
Interventional 30 participants sought
Ohio State University Comprehensive Cancer Center — Columbus, Ohio (1.9 mi)
· Sponsor: Dwight Owen
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma
Phase 1
Interventional 168 participants sought
Ohio State University — Columbus, Ohio (1.9 mi)
· Sponsor: OncoNano Medicine, Inc.
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
Phase 2
Interventional 222 participants sought
Nationwide Children's Hospital — Columbus, Ohio (1.9 mi)
· Sponsor: National Cancer Institute (NCI)
MicroRNAs as Biomarkers for Obstructive Sleep Apnea
Obstructive Sleep Apnea
N/A
Observational 500 participants sought
The Ohio State University - Martha Morehouse Medical Pavilion, Suite 2600 — Columbus, Ohio (1.9 mi)
· Sponsor: University of Pennsylvania
Outreach Project to Connect Underrepresented Populations to Clinical Trials at Ohio State University, CUSP2CT Project Trial
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
N/A
Interventional 208 participants sought
Ohio State University Comprehensive Cancer Center — Columbus, Ohio (1.9 mi)
· Sponsor: Ohio State University Comprehensive Cancer Center
Cardiothoracic Critical Care as Subspecialty and Its Core Competencies
Consensus Development
N/A
Observational 68 participants sought
The Ohio State University Wexner Medical Center — Columbus, Ohio (1.9 mi)
· Sponsor: Ohio State University
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
Diffuse Intrinsic Pontine Gliomas (DIPG), Progressive DIPG
Phase 2
Interventional 60 participants sought
Nationwide Children's Hospital — Columbus, Ohio (1.9 mi)
· Sponsor: Nationwide Children's Hospital
Studying the Health Perceptions and Social Behaviors of Graduate Students at the Ohio State University for the Development of Effective Oral Nicotine Pouch Addictive Risk Communication
Tobacco-Related Carcinoma
N/A
Interventional 2,000 participants sought
Ohio State University Comprehensive Cancer Center — Columbus, Ohio (1.9 mi)
· Sponsor: Ohio State University Comprehensive Cancer Center
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
NK-Cell Lymphoma, NK-Cell Leukemia
EARLY/Phase 1
Interventional 40 participants sought
Nationwide Children's Hospital — Columbus, Ohio (1.9 mi)
· Sponsor: New York Medical College
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
Ohio State University Comprehensive Cancer Center — Columbus, Ohio (1.9 mi)
· Sponsor: SWOG Cancer Research Network
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Phase 2
Interventional 81 participants sought
Ohio State University Comprehensive Cancer Center — Columbus, Ohio (1.9 mi)
· Sponsor: National Cancer Institute (NCI)
Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)
Diabetes Mellitus, Type 2
N/A
Interventional 119,680 participants sought
The Ohio State University — Columbus, Ohio (1.9 mi)
· Sponsor: Stanford University
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
Limited Stage Small Cell Lung Cancer
Phase 2
Interventional 250 participants sought
The Ohio State University - Arthur James Cancer Hospital & Solove Research Institute — Columbus, Ohio (1.9 mi)
· Sponsor: SCRI Development Innovations, LLC
Waveform Capnography Compared to Colorimetric Carbon Dioxide Detection During Tracheal Intubation of Critically Ill Adults
Acute Respiratory Failure
N/A
Observational 2,092 participants sought
The Ohio State University College of Medicine — Columbus, Ohio (1.9 mi)
· Sponsor: Brian Driver
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Endometrial Cancer
Phase 3
Interventional 600 participants sought
Research Site — Columbus, Ohio (1.9 mi)
· Sponsor: AstraZeneca
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Acute Myeloid Leukemia (AML)
Phase 3
Interventional 1,300 participants sought
Ohio State University — Columbus, Ohio (1.9 mi)
· Sponsor: Kura Oncology, Inc.
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
Lewy Body Dementia Psychosis
Phase 2
Interventional 180 participants sought
The Ohio State University, Energy Advancement and Innovation Center — Columbus, Ohio (1.9 mi)
· Sponsor: ACADIA Pharmaceuticals Inc.
A Study of Buntanetap in Participants With PD
Parkinson's Disease (PD), Deep Brain Stimulation
Phase 2, Phase 3
Interventional 500 participants sought
The Ohio State University Wexner Medical Center — Columbus, Ohio (1.9 mi)
· Sponsor: Annovis Bio Inc.
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Carcinoma, Non-Small-Cell Lung
Phase 1, Phase 2
Interventional 450 participants sought
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0015) — Columbus, Ohio (1.9 mi)
· Sponsor: Merck Sharp & Dohme LLC
MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Adamantinous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
Phase 2
Interventional 38 participants sought
Nationwide Children's Hospital — Columbus, Ohio (1.9 mi)
· Sponsor: Nationwide Children's Hospital
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
AML, Adult Recurrent, ALL, Recurrent, Adult
Phase 1, Phase 2
Interventional 38 participants sought
The Ohio State University — Columbus, Ohio (1.9 mi)
· Sponsor: BlueSphere Bio, Inc
E-Mindfulness Approaches for Living After Breast Cancer
Breast Cancer, Depression
Phase 3
Interventional 402 participants sought
Ohio State University Comprehensive Cancer Center — Columbus, Ohio (1.9 mi)
· Sponsor: NRG Oncology
A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity
EGFR Inhibitor-associated Rash
Phase 1, Phase 2
Interventional 32 participants sought
The Ohio State University — Gahanna, Ohio (6.1 mi)
· Sponsor: Azitra Inc.
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma
Phase 2
Interventional 40 participants sought
Ohio State University Comprehensive Cancer Center — Columbus, Ohio (1.9 mi)
· Sponsor: Sameek Roychowdhury